Nivolumab plus ipilimumab in advanced melanoma (Q27852310)

14 December 2017

Nivolumab plus ipilimumab in advanced melanoma (English)

1 reference

14 December 2017

0 references

0 references

0 references

24

Mario Sznol

1 reference

14 December 2017

1

Jedd D Wolchok

1 reference

14 December 2017

4

Michael A Postow

1 reference

14 December 2017

6

Alexander M Lesokhin

1 reference

14 December 2017

Harriet Kluger

2

1 reference

14 December 2017

Margaret K Callahan

3

1 reference

14 December 2017

Naiyer A Rizvi

5

1 reference

14 December 2017

Neil H Segal

7

1 reference

14 December 2017

Charlotte E Ariyan

8

1 reference

14 December 2017

Ruth-Ann Gordon

9

1 reference

14 December 2017

Kathleen Reed

10

1 reference

14 December 2017

Matthew M Burke

11

1 reference

14 December 2017

Anne Caldwell

12

1 reference

14 December 2017

Stephanie A Kronenberg

13

1 reference

14 December 2017

Blessing U Agunwamba

14

1 reference

14 December 2017

Xiaoling Zhang

15

1 reference

14 December 2017

Israel Lowy

16

1 reference

14 December 2017

Hector David Inzunza

17

1 reference

14 December 2017

William Feely

18

1 reference

14 December 2017

Christine E Horak

19

1 reference

14 December 2017

Quan Hong

20

1 reference

14 December 2017

Alan J Korman

21

1 reference

14 December 2017

Jon M Wigginton

22

1 reference

14 December 2017

Ashok Gupta

23

1 reference

14 December 2017

language of work or name

English

0 references

publication date

2 June 2013

1 reference

The New England Journal of Medicine

14 December 2017

1 reference

14 December 2017

369

1 reference

14 December 2017

2

1 reference

14 December 2017

122-133

1 reference

on focus list of Wikimedia project

14 December 2017

ScienceSource

0 references

cites work

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Hallmarks of Cancer: The Next Generation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Toxicity and response criteria of the Eastern Cooperative Oncology Group

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5698004

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

2 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23724867

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1302369

1 reference

OpenCitations bibliographic resource ID

14 December 2017

733191

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

14 December 2017

PubMed publication ID

23724867

1 reference